Letter to CSPI et al. from Dr. Peter Marks
![FDA Warns Joseph Mercola Not to Market Products Making Fake Claims to Treat or Prevent COVID-19](/sites/default/files/styles/700x530/public/media/images/detail/fdalogo.png?h=696eae02)
Director of FDA's CBER Responds to CSPI Letter
Dr. Peter Marks, director of the Food and Drug Administration’s Center for Biologics Evaluation and Research, responded to a CSPI-organized letter from 400 prominent experts in vaccine technology, epidemiology, virology, and other public health fields urging that the FDA not make a COVID-19 vaccine widely available until Phase 3 clinical trials are complete.